| Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling AA Alizadeh, MB Eisen, RE Davis, C Ma, IS Lossos, A Rosenwald, ... Nature 403 (6769), 503-511, 2000 | 12653 | 2000 |
| Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study P Fenaux, GJ Mufti, E Hellstrom-Lindberg, V Santini, C Finelli, ... The lancet oncology 10 (3), 223-232, 2009 | 3052 | 2009 |
| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia JC Byrd, RR Furman, SE Coutre, IW Flinn, JA Burger, KA Blum, B Grant, ... New England Journal of Medicine 369 (1), 32-42, 2013 | 2825 | 2013 |
| Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid … JC Byrd, K Mrózek, RK Dodge, AJ Carroll, CG Edwards, DC Arthur, ... Blood, The Journal of the American Society of Hematology 100 (13), 4325-4336, 2002 | 2102 | 2002 |
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ... New England Journal of Medicine 371 (3), 213-223, 2014 | 1986 | 2014 |
| iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL M Hallek, BD Cheson, D Catovsky, F Caligaris-Cappio, G Dighiero, ... Blood, The Journal of the American Society of Hematology 131 (25), 2745-2760, 2018 | 1736 | 2018 |
| Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia A Rosenwald, AA Alizadeh, G Widhopf, R Simon, RE Davis, X Yu, L Yang, ... The Journal of experimental medicine 194 (11), 1639-1648, 2001 | 1456 | 2001 |
| Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib JA Woyach, RR Furman, TM Liu, HG Ozer, M Zapatka, AS Ruppert, L Xue, ... New England Journal of Medicine 370 (24), 2286-2294, 2014 | 1395 | 2014 |
| Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study MJ Keating, I Flinn, V Jain, JL Binet, P Hillmen, J Byrd, M Albitar, ... Blood, The Journal of the American Society of Hematology 99 (10), 3554-3561, 2002 | 1245 | 2002 |
| ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia LZ Rassenti, L Huynh, TL Toy, L Chen, MJ Keating, JG Gribben, ... New England Journal of Medicine 351 (9), 893-901, 2004 | 1216 | 2004 |
| Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia JC Byrd, B Harrington, S O’Brien, JA Jones, A Schuh, S Devereux, ... New England Journal of Medicine 374 (4), 323-332, 2016 | 1047 | 2016 |
| Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 SEM Herman, AL Gordon, E Hertlein, A Ramanunni, X Zhang, ... Blood, The Journal of the American Society of Hematology 117 (23), 6287-6296, 2011 | 1014 | 2011 |
| Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL JA Woyach, AS Ruppert, NA Heerema, W Zhao, AM Booth, W Ding, ... New England Journal of Medicine 379 (26), 2517-2528, 2018 | 1007 | 2018 |
| The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody DM Benson Jr, CE Bakan, A Mishra, CC Hofmeister, Y Efebera, ... Blood, The Journal of the American Society of Hematology 116 (13), 2286-2294, 2010 | 965 | 2010 |
| MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly … R Garzon, S Liu, M Fabbri, Z Liu, CEA Heaphy, E Callegari, S Schwind, ... Blood, The Journal of the American Society of Hematology 113 (25), 6411-6418, 2009 | 932 | 2009 |
| Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype CD Bloomfield, D Lawrence, JC Byrd, A Carroll, MJ Pettenati, ... Cancer research 58 (18), 4173-4179, 1998 | 912 | 1998 |
| CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability BJ Lannutti, SA Meadows, SEM Herman, A Kashishian, B Steiner, ... Blood, The Journal of the American Society of Hematology 117 (2), 591-594, 2011 | 880 | 2011 |
| Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib JC Byrd, RR Furman, SE Coutre, JA Burger, KA Blum, M Coleman, ... Blood, The Journal of the American Society of Hematology 125 (16), 2497-2506, 2015 | 864 | 2015 |
| Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes JA Dubovsky, KA Beckwith, G Natarajan, JA Woyach, S Jaglowski, ... Blood, The Journal of the American Society of Hematology 122 (15), 2539-2549, 2013 | 850 | 2013 |
| Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. JC Byrd, WJ Edenfield, DJ Shields, NA Dawson Journal of Clinical Oncology 13 (7), 1800-1816, 1995 | 804 | 1995 |
